Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis

Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022996

Enrollment

Registered

2016-07-04

Start date

2016-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial sarcoidosis

Interventions

mediacl therapy with methotrexate medical therapy with steroid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Myocardial sarcoidosis

Exclusion criteria

Exclusion criteria: The patients with myelosuppression, chronic liver dysfunction, chronic kidney disease and infection.

Design outcomes

Primary

Measure	Time frame
The change of uptaking area estimated by 18F-FDG PET/CT	—

Secondary

Measure	Time frame
Frequency of sudden cardiac death, lethal arrhythmia and heart failure.	—

Countries

Japan

Contacts

Public ContactToyoaki Murohara

Nagoya University Graduate School of Medicine Cardiology

ryota.m0726@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026